A review of edible plant-derived natural compounds for the therapy of liver fibrosis. Issue 2 (8th December 2022)

• Record Type: Journal Article
• Authors: Xu, Wenjuan; Wang, Longde; Niu, Yuanyuan; Mao, Lanfang; Du, Xiaojuan; Zhang, Ping; Li, Zhengju; Li, Hongfang; Li, Ning
• Is Part Of: European journal of gastroenterology & hepatology. Volume 35:Issue 2(2023)
• Page Start: 133
• Page End: 152
• Publication Date: 2022-12-08
• Subjects: antifibrotic therapy -- edible plant -- hepatic stellate cells -- liver disease -- liver fibrosis -- natural compound; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Digestive organs -- Diseases; Liver -- Diseases; Periodicals; 616.33
• DOI: 10.1097/MEG.0000000000002483
• Languages: English
• ISSNs: 0954-691X

Abstract

Abstract : Liver fibrosis has a high incidence worldwide and is the common pathological basis of many chronic liver diseases. Liver fibrosis is caused by the excessive deposition of extracellular matrix and concomitant collagen accumulation in livers and can lead to the development of liver cirrhosis and even liver cancer. A large number of studies have provided evidence that liver fibrosis can be blocked or even reversed by appropriate medical interventions. However, the antifibrosis drugs with ideal clinical efficacy are still insufficient. The edible plant-derived natural compounds have been reported to exert effective antifibrotic effects with few side-effects, representing a kind of promising source for the treatment of liver fibrosis. In this article, we reviewed the current progress of the natural compounds derived from dietary plants in the treatment of liver fibrosis, including phenolic compounds (capsaicin, chlorogenic acid, curcumin, ellagic acid, epigallocatechin-3-gallate, resveratrol, sinapic acid, syringic acid, vanillic acid and vitamin E), flavonoid compounds (genistein, hesperidin, hesperetin, naringenin, naringin and quercetin), sulfur-containing compounds (S-allylcysteine, ergothioneine, lipoic acid and sulforaphane) and other compounds (betaine, caffeine, cucurbitacin B, lycopene, α-mangostin, γ-mangostin, ursolic acid, vitamin C and yangonin). The pharmacological effects and related mechanisms of these compounds in in-vivo and in-vitro models of liver fibrosis are focused.